

NACT, Riga 23.05.2024

Alexander Sartorius

Central Institute of Mental Health (CIMH)





COI – none, but:





Ketamine and ECT:



plus

ECT



story of this talk ...



alternating with





might act a little faster ...



versus






Pouya! (next talk)

Ketamine and ECT:



alternating with






As a next step in our treatment algorithm, we commenced off-label intravenous esketamine treatment dosed at 0.5 mg/kg, which was increased to 0.75 mg/kg after 3 weeks because of insufficient effectiveness. Initially, 9 esketamine infusions were administered. Only a slight improvement of mood and inner restlessness occurred. At the end of the first esketamine series, the MADRS score was 36.

Because only insufficient response with ECT as well as with intravenous esketamine was achieved, a treatment algorithm of a combination of ECT and esketamine infusions on non-ECT days was considered. After a total of 6 bilateral ECT sessions (3 ECTs per week) and 4 esketamine infusions dosed at 1 mg/kg applied on non-ECT days, the patient showed rapid and significant clinical improvement. During the second week of combination treatment, lithium was discontinued because of mild disorientation, which subsided quickly after discontinuation of lithium. Otherwise, the combination treatment of ECT and esketamine was tolerated well without any relevant complications.

The combination treatment of ECT and esketamine resulted in a reduction of the MADRS score from 36 to 9 within 18 days. Less than 3 weeks after the beginning of the combination treatment, the patient was discharged from hospital. For relapse prevention, we began lithium maintenance at the previous dose and level and continued with the medication as commenced before the combination treatment of ECT and esketamine.

Kavakbasi E, Hassan A, Baune BT. Combination of Electroconvulsive Therapy Alternating With Intravenous Esketamine Can Lead to Rapid Remission of Treatment Resistant Depression. J ECT. 2021 Jun 1;37(2):e20-e21.



Per HAMD scores, 3 of the 7 ECT + ketamine subjects (42%) showed early response and remission and maintained euthymia for 3 additional visits, where one ECT +midazolam patient showed early response but this effect was not sustained, therefore none of the ECT + midazolam subjects (0%) achieved early remission .

Altinay M, Karne H, Anand A. Administration of Sub-anesthetic Dose of Ketamine and Electroconvulsive Treatment on Alternate Week Days in Patients with Treatment Resistant Depression: A Double Blind Placebo Controlled Trial. Psychopharmacol Bull. 2019 Feb 15;49(1):8-16.

Ketamine and ECT:



plus

ECT



story of this talk ...



alternating with





might act a little faster ...



versus





Pouya! (next talk)

Ketamine and ECT: Why we would like to quantify seizure quality?




age, severity, therapy resistance, episodicity, heritibility

Charge!

fixed

change with every ECT possible



1 Older Age Is Associated with Rapid Remission of Depression After Electroconvulsive Therapy: A Latent Class Growth Analysis.

Rhebergen et al., Am J Geriatr Psychiatry. 2014

2 Appropriateness for ECT can be assessed on a three-item scale.


Kellner CH, Med Hypotheses. 2012

3 A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities.


Sackeim HA, Arch Gen Psychiatry. 2000

Ketamine and ECT: Why we would like to quantify seizure quality?





Optimising the seizure



Possible markers:

- seizure concordance
- postictal suppression index
- seizure energy index
- motor response time
- duration of EEG seizure activity
- peak heart rate
- midictal amplitude
- total seizure coherence

160% RUL

Optimising the seizure



Possible markers:

- seizure concordance
- postictal suppression index
- seizure energy index
- motor response time
- duration of EEG seizure activity
- peak heart rate
- midictal amplitude
- total seizure coherence

30% RUL

Seizure Duration

Table 2Mixed effects linear regression of log-transformed seizure duration on sex, age, treatment dose, and treatment number, with a knot placed at the third treatment.

| | Seizure Duration (w/Knot at tx #3) | | | | | | | |
|--|------------------------------------|--|---|--|--|--|--|--|
| Predictors | Estimates | CI | p | | | | | |
| Sex (male) Age (z-score) Dose (z-score) Treatment number | $-0.02 \\ -0.14 \\ -0.06$ | -0.06 - 0.02 $-0.16 - 0.12$ $-0.08 - 0.05$ | 0.265 < 0.001 < 0.001 | | | | | |
| #1 - #3 #3 - #12 | $-0.28 \\ -0.01$ | -0.300.26 $-0.020.01$ | <0.001 <0.001 | | | | | |




N= 3648 Patients included:

Seizure markes are strongly age dependent

Z


Fig. 1 Negative correlation between age and SQI. Line fits represent linear regression and 95% confidence interval



Sartorius A, Beuschlein J, Remennik D, Pfeifer AM, Karl S, Bumb JM, Aksay SS, Kranaster L, Janke C. Empirical ratio of the combined use of S-ketamine and propofol in electroconvulsive therapy and its impact on seizure quality. Eur Arch Psychiatry Clin Neurosci. 2021 Apr;271(3):457-463.


Seizure?






ECT and the bad anesthesiologist





Outcome and ECT anaesthesia - thiopental






A. Sartorius et al., ECT anesthesia: the lighter the better? Pharmacopsychiatry. 2006 Nov;39(6):201-4.

Outcome and ECT anaesthesia: Thiopental / Propofol => Response

| | N included | Response/remission/memory worsening, % | Crude odds ratio (95% CI) | <i>P</i> -value | Adjusted odds ratio (95% CI) | <i>P</i> -value |
|---|--------------|--|---------------------------------|-----------------|------------------------------------|-----------------|
| Doctores CCLL | 7V IIIciaaca | Worselling, 70 | (7370 01) | r-value | (73 /0 CI) | r-value |
| Response, CGI-I Low-dose interval | 3140 | 75.7% | 1.27 (1.11–1.45) | < 0.001 | 1.22 (1.07–1.40) | 0.004 |
| Medium-dose interval | 2266 | 74.8% | 1.21 (1.05–1.39) | 0.008 | 1.15 (1.00–1.33) | 0.056 |
| | 1805 | 74.8% | Reference | Reference | Reference | Reference |
| High-dose interval | 1805 | 71.1% | Reference | Reference | Reference | Reference |
| Distinct response, CGI-I Low-dose interval | 2140 | 22.70/ | 1 (0 (1 (0 1 92) | -0.001 | 1 51 /1 22 1 72\ | -0.001 |
| | 3140 | 32.7% | 1.60 (1.40–1.83) | <0.001 | 1.51 (1.32–1.73) | <0.001 |
| Medium-dose interval | 2266 | 29.4% | 1.37 (1.19–1.58) | <0.001 | 1.32 (1.14–1.53) | <0.001 |
| High-dose interval | 1805 | 23.3% | Reference | Reference | Reference | Reference |
| Remission, CGI-S | 0050 | 00.004 | 4 40 (4 07 4 70) | 0.004 | 107 (117 1 (0) | 0.004 |
| Low-dose interval | 2950 | 23.0% | 1.48 (1.27–1.72) | < 0.001 | 1.37 (1.17–1.60) | < 0.001 |
| Medium-dose interval | 2134 | 21.6% | 1.36 (1.16–1.60) | < 0.001 | 1.30 (1.10–1.54) | 0.002 |
| High-dose interval | 1716 | 16.8% | Reference | Reference | Reference | Reference |
| Response, MADRS-S | | | | | | |
| Low-dose interval | 1470 | 65.4% | 1.39 (1.17–1.65) | < 0.001 | 1.31 (1.09-1.56) | 0.004 |
| Medium-dose interval | 1026 | 60.7% | 1.13 (0.94-1.36) | 0.180 | 1.06 (0.87-1.28) | 0.556 |
| High-dose interval | 889 | 57.7% | Reference | Reference | Reference | Reference |
| Remission, MADRS-S | | | | | | |
| Low-dose interval | 1801 | 43.9% | 1.45 (1.24–1.70) | < 0.001 | 1.31 (1.11-1.55) | 0.002 |
| Medium-dose interval | 1210 | 39.7% | 1.22 (1.03–1.45) | 0.023 | 1.13 (0.94-1.36) | 0.18 |
| High-dose interval | 1031 | 35.0% | Reference | Reference | Reference | Reference |
| Subjective memory worsen | ing | | | | | |
| Low-dose interval | 1923 | 21.6% | 1.34 (1.11-1.62) | 0.002 | 1.32 (1.09-1.60) | 0.004 |
| Medium-dose interval | 1398 | 17.0% | 1.00 (0.81-1.22) | 0.971 | 0.99 (0.80-1.22) | 0.893 |
| High-dose interval | 1176 | 17.0% | Reference | | Reference | |

For each outcome, the table shows the number of included patients (if patients had missing data on the outcome they were excluded from the logistic regression models). The proportion of each outcome. Crude odds ratios and their 95% confidence intervals were calculated by correlating the age and gender-adjusted dose intervals and the outcomes without any further variables. A regression model adjusted for age, gender, number of treatments, psychiatric comorbidity and psychiatric pharmacotherapy was used to calculate adjusted odds ratios and their 95% confidence intervals. *P*-values are shown for both crude and adjusted odds ratios separately. CGI-S, Clinical Global Impression – Severity Scale; CGI-I, Clinical Global Impression – Improvement Scale; MADRS-S, Montgomery–Åsberg Depression Rating Scale, self-rated version.

dose-dependent response and remission



The effect of anaesthetic dose on response and remission in electroconvulsive therapy for major

remission in electroconvulsive therapy for major depressive disorder: nationwide register-based cohort study

Alexander Kronsell, Axel Nordenskjöld, Max Bell, Ridwanul Amin, Ellenor Mittendorfer-Rutz and Mikael Tiger

ECT anaesthesia

| substance | typical dose range (mg/kg) | anticonvulsive effect (relative) | remarks | | |
|--------------|-------------------------------|----------------------------------|---|--|--|
| methohexital | 0,75-1.0 | 1-2 | former gold standard, cardiovascular depression | | |
| thiopental | 2-5 | 2 | cardiovascular depression | | |
| propofol | 1-2 | 3 | shorter seizures, higher seizure threshold | | |
| etomidate | 0.2-0.3 | 0 | myocloni | | |
| S-ketamine | 0.5-1.5 | 0 | low doses pro-psychotic, higher blood pressure | | |
| alfentanil | 0.01-0.015 | 0 | longer time of apnoe, cardiovascular depression | | |
| remifentanil | 0.001-0.008 | 1 | similar to alfentanil ? | | |



Rote-Hand-Briefe

Folkerts HW.

Adapted from:

Electroconvulsive therapy. Indications, procedure and treatment results Nervenarzt. 2011 Jan;82(1):93-102

Swartz CM

Electroconvulsive and neuromodulation therapies.
2009 Cambridge Univ, Cambridge New York Melbourne

* Hikma Pharmaceuticals stopped the production of methohexital 2019-2022

** Good Manufacturing Practice (GMP) problems at Lampugnani Pharmaceutici SPA

** In Cormony, more ar loss cheelete for critically ill notion to and for non-circle industing


* In Germany: more or less obsolete for critically ill patients and for non-single induction use

ECT anaesthesia - ketamine


Z

ketamine in general anesthesia:

- is listed as an essential drug by the WHO
- often used in emergeny medicine
- treatment of status asthmaticus
- analgesia of intubated patients
- preferred for childs and ado's








- still in use for general and regional anesthesia (alone and in combination with hypnotics)
- off-label for chronic pain patients

ECT anaesthesia: Ketamine






The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Vollenweider FX, Kometer M. Nat Rev Neurosci. 2010 Sep;11(9):642-51.


ECT anaesthesia - ketamine





Impact of ketamine, etomidate, thiopental and propofol as anesthetic on seizure parameters and seizure quality in electroconvulsive therapy: A retrospective study Carolin Hoyer, Laura Kranaster, Christoph Janke, Alexander Sartorius

Eur Arch Psychiatry Clin Neurosci 2014 Apr;264(3):255-61.



Ekstrand J, Fattah C, Persson M, Cheng T, Nordanskog P, Åkeson J, Tingström A, Lindström MB, Nordenskjöld A, Movahed Rad P. Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT). Int J Neuropsychopharmacol. 2022 May 27;25(5):339-349

patients receiving ECT, 63% remitted compared with 46% receiving

ketamine infusions".

zi

Thus – hypothetically – there are 2 good reasons why it should:

 Ketamine does not increase seizure threshold – since it is no anticonvulsant

- Ketamine acts as an antidepressant itself





Abstract

The authors retrospectively compared the seizure duration, ictal EEG, and cognitive side effects of ketamine and methohexital anesthesia with ECT. This comparison was carried out with data from consecutive index ECT treatments that occurred immediately before and after a switch from methohexital to ketamine in 36 patients. Ketamine was well tolerated and prolonged seizure duration overall, but particularly in those who had a seizure duration shorter than 25 seconds with methohexital at the maximum available stimulus intensity. Ketamine also increased midictal EEG slow-wave amplitude. Thus, a switch to ketamine may be useful when it is difficult to elicit a robust seizure. Faster post-treatment reorientation with ketamine may suggest a lower level of associated cognitive side effects.

Krystal AD, Weiner RD, Dean MD, Lindahl VH, Tramontozzi LA 3rd, Falcone G, Coffey CE. Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT. J Neuropsychiatry Clin Neurosci. 2003 Winter;15(1):27-34.







Kranaster L, Kammerer-Ciernioch J, Hoyer C, Sartorius A. Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study. Eur Arch Psychiatry Clin Neurosci. 2011 Dec;261(8):575-82.

Does Ketamine improve ECT ? => add-on studies...




two recent examples

RCT (n=45):

propofol at 1.2 mg/kg plus 0.2 mg/kg or 0.5 mg/kg

=> No differences.


Woolsey AJ, Nanji JA, Moreau C, Sivapalan S, Bourque SL, Ceccherini-Nelli A, Gragasin FS. Lowdose ketamine does not improve the speed of recovery from depression in electroconvulsive therapy: a randomized controlled trial. Braz J Psychiatry. 2022 Jan-Feb;44(1):6-14.



- "thiopental 1.5–3 mg/kg"
- "30–100 joules of electric shock"

Modir H, Mahmoodiyeh B, Shayganfard M, Abdus A, Almasi-Hashiani A. Efficacy of ketamine, propofol, and dexmedetomidine for anesthesia in electroconvulsive therapy in treatment-resistant major depressive disorder patients: a double-blind randomized clinical trial. Med Gas Res. 2023 Jul-Sep;13(3):112-117.






results from just "adding" another substance are quite evident:

- no improvements
- more side effects

Ren L, Yu J, Zeng J, Wei K, Li P, Luo J, Shen Y, Lv F, Min S. Comparative efficacy and tolerability of different anesthetics in electroconvulsive therapy for major depressive disorder: A systematic review and network meta-analysis. J Psychiatr Res. 2024 Mar;171:116-125.

ECT anaesthesia – ketamine – at least faster than propofol





Test for subgroup differences: $Chi^2 = 2.32$. df = 2 (P = 0.31). $I^2 = 13.8\%$

Figure 2 The ketamine group versus the propofol group: forest plot for depressive symptoms at days 1, 3 and 7 after a single electroconvulsive therapy session.

Li XM, Shi ZM, Wang PJ, Hu H. Effects of ketamine in electroconvulsive therapy for major depressive disorder: meta-analysis of randomised controlled trials. Gen Psychiatr. 2020;33(3):e100117.

ECT and ketamine - response

| Model | Study name | Subgroup within study | Outcome | Sampl | e size | Statistics for each study | | | | Weight (Random) | Hedges's g and 95% CI | |
|--------|--------------|-----------------------|----------|---------|---------|---------------------------|----------------|----------------|---------|-----------------|-----------------------|----------------------------|
| | | | | Ketamin | Control | Hedges's | Lower limit | Upper limit | Z-Value | p-Value | Relative weight | |
| | Abdallah | K+ | Combined | 7 | 7 | -0.288 | -1.275 | 0.700 | -0.571 | 0.568 | 6.95 | + |
| | Jarventausta | K+ | Combined | 15 | 13 | -0.229 | -0.968 | 0.510 | -0.607 | 0.544 | 9.07 | + |
| | Shams | K+ | Hamilton | 22 | 20 | 0.009 | -0.585 | 0.603 | 0.030 | 0.976 | 10.52 | + |
| | Yoosefi | K only | Hamilton | 15 | 14 | 0.200 | -0.510 | 0.910 | 0.552 | 0.581 | 9.35 | + |
| | Zhong | Combined | Hamilton | 60 | 60 | 1.020 | 0.640 | 1.400 | 5.258 | 0.000 | 12.72 | + |
| | Anderson | K+ | Combined | 27 | 32 | -0.257 | -0.765 | 0.250 | -0.993 | 0.320 | 11.43 | + |
| | Ray-Griffith | K only | Combined | 8 | 8 | 0.202 | -0.728 | 1.131 | 0.425 | 0.671 | 7.39 | + |
| | Fernie | K only | Combined | 16 | 17 | -0.756 | -1.447 | -0.065 | -2.145 | 0.032 | 9.54 | + |
| | Zhang | K+ | Combined | 43 | 34 | 0.213 | -0.234 | 0.660 | 0.934 | 0.350 | 12.06 | + |
| | Carspecken | K only | Combined | 23 | 27 | 0.334 | -0.217 | 0.886 | 1.188 | 0.235 | 10.97 | |
| Random | | | | 236 | 232 | 0.084 | -0.272 | 0.441 | 0.465 | 0.642 | | |
| | | | | | | | | | | | | -4.00 -2.00 0.00 2.00 4.00 |

Ainsworth NJ, Sepehry AA, Vila-Rodriguez F.

Effects of Ketamine Anesthesia on Efficacy, Tolerability, Seizure Response, and Neurocognitive Outcomes in Electroconvulsive Therapy:

A Comprehensive Meta-analysis of Double-Blind Randomized Controlled Trials.

A Comprehensive Meta-analysis of Double-Blind Randomized Controlled Trials J ECT. 2020 Jun;36(2):94-105.

ECT anaesthesia – ketamine – dose (charge)

| Model | Study name | Subgroup within study | Sample | e size | | Statistics for each study | | | | Weight (Random) | Hedges's g and 95% CI |
|--------|------------|-----------------------|-----------|---------|----------|---------------------------|----------------|---------|---------|-----------------|----------------------------------|
| | | | Treatment | Control | Hedges's | Lower limit | Upper limit | Z-Value | p-Value | Relative weight | |
| | Anderson | K+ | 33 | 37 | -0.158 | -0.622 | 0.307 | -0.664 | 0.506 | 25.51 | + |
| | Carspecken | K only | 23 | 27 | 0.350 | -0.202 | 0.901 | 1.242 | 0.214 | 25.35 | + |
| | Zhang | K+ | 43 | 34 | 6.633 | 5.495 | 7.771 | 11.421 | 0.000 | 23.66 | |
| | Zhong | Combined | 60 | 60 | 1.421 | 0.940 | 1.902 | 5.796 | 0.000 | 25.48 | + |
| Random | | | 159 | 158 | 1.980 | 0.106 | 3.853 | 2.071 | 0.038 | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | -4.00 -2.00 0.00 2.00 4.00 |
| | | | | | | | | | | | Favours Control Favours Ketamine |

FIGURE 5. Forest plot of meta-analysis results for electrical dose. Numbers along *x* axis of graph denote effect size as Hedge's *g*; results to the right favor ketamine. Diamond edges denote 95% confidence interval. *Z* value and *P* value represent the test for overall effect. Relative weight is expressed as percent of total. K only, patient groups receiving ketamine as sole anesthetic; K+, patient groups receiving ketamine in combination with another anesthetic; combined, results pooled from both K+ and K only groups in study.

Ainsworth NJ, Sepehry AA, Vila-Rodriguez F.

Effects of Ketamine Anesthesia on Efficacy, Tolerability, Seizure Response, and Neurocognitive Outcomes in Electroconvulsive Therapy:

A Comprehensive Meta-analysis of Double-Blind Randomized Controlled Trials. J ECT. 2020 Jun;36(2):94-105.

Does Ketamine improve ECT? Latest Meta-Analsis








Fig. 4 Rankograms of surface under the cumulative ranking (SUCRA) curves by each outcome measure. A Depressive symptoms. B Cognitive performance. C Remission. D Response. E Serious adverse events. Note: Graphical summary of P-scores of different interventions in the course of electroconvulsive therapy for major depressive episode. Higher and closer-to-1 P-scores indicate greater likelihood of top-rank interventions. Placebo refers to "thiopental plus saline"


Rhee TG, Shim SR, Popp JH, Trikalinos TA, Rosenheck RA, Kellner CH, Seiner SJ, Espinoza RT, Forester BP, McIntyre RS. Efficacy and safety of ketamine-assisted electroconvulsive therapy in major depressive episode: a systematic review and network meta-analysis. Mol Psychiatry. 2023 Dec 20.

taking up a lance for "ketofol"



Take home from own study:


- Propofol still negatively impacts SQI at doses as low as
- Empirical ratio of S-Ketamin / propofol was



Sartorius A, Beuschlein J, Remennik D, et al. Empirical ratio of the combined use of S-ketamine and propofol in electroconvulsive therapy and its impact on seizure quality [published online ahead of print, 2020 Jul 22]. *Eur Arch Psychiatry Clin Neurosci*.

ECT anaesthesia – ASTI if propofol is still applied





Optimising the seizure (and the outcome)



- lower the ST by flumazenil or caffeine if necessary
- be generous with hyperoxigenation
- use ketamine / etomidate if possible
- use ketamine / etomidate / remifentanil as augmentation to propofol / barbiturates
- take enough time between start of propofol / barbiturates and stimulation (ASTI)
- take into account that ST can rise dramatically during ECT series increase dose




- don't spare to much anesthesia dose risk of PIA!
- don't spare to much charge risk of underdosing / stimulation at or around ST

Problems

zi

A widespread myth: Ketamine anesthesia - recovery room




No prolongation of time spent in recovery room by ketamine, but by age.

Sartorius A, Beuschlein J, Remennik D, Pfeifer AM, Karl S, Bumb JM, Aksay SS, Kranaster L, Janke C. Empirical ratio of the combined use of S-ketamine and propofol in electroconvulsive therapy and its impact on seizure quality. Eur Arch Psychiatry Clin Neurosci. 2021 Apr;271(3):457-463.

Problems Ketamine anaesthesia: hypersalivation





risk factors:

- smoking
- ketamine
- drugs like e.g. clozapine
- and: parasympathetic stimulation

Problems Ketamine anaesthesia - hypersalivation / sialorrhoe



- Former times: atropine, which is basically obsolete.

- Today: glycopyrrolate as a muscarinic receptor antagonist


- Both reduce hypersalivation (parasympatholytic)
- atropine reduces initial bradycardia, but increases ictal hypertension *

P, Olsen NV, Jørgensen MB.

^{*} Psychiatry Res. 2019 Jan;271:239-246
Electro convulsive therapy: Modification of its
effect on the autonomic nervous system using anticholinergic drugs.
Christensen STJ, Staalsø JM, Jørgensen A, Weikop

Still an alternative: anaesthesia with etomidate






JAMA Surgery | Original Investigation

Effect of Etomidate vs Propofol for Total Intravenous Anesthesia on Major Postoperative Complications in Older Patients

A Randomized Clinical Trial

Figure 2. In-Hospital Complications for Etomidate and Propofol Groups





Yes, if you are NOT just adding a new substance (i.e. ketamine) and keep doses constant, but use solely ketamine OR ketamine plus a massively reduced other anesthetic (i.e. propofol):

- (maybe) better remission rates
- better depressive symptom reduction
- less charge needed and => less cognitive side effects!
- more hypersalivation, but no longer time needed in the recovery room



NACT Board (may 22nd): Performing ECT at a High-Quality Level Is a Team Effort



Elisabeth Burgunder



Laura Kranaster



Suna Su Aksay



Jan Malte Bumb



Sebastian Karl



Sina Edinger und Petra Mychajluk



and:

Lana Said


Kent-Tjorben Böttcher
Gerrit Breitfelder
Sina Edinger
Christoph Janke
Eva Lamadé
Jessica Mächnich
Petra Mychajluk
Franziska Putschögl
Jonathan Reinwald
Moritz Spangemacher
Angela Zapp



for your attention

www.zi-mannheim.de alexander.sartorius@zi-mannheim.de

Dose increase over ECT series is even faster with age



Interaction between age, ongoing ECT number [0-14] and stimulation dose [charge]

Division of age quartils: 1: < 42 years; 2: \geq 42 years to 59 years; 3: \geq 59 years to 73 years; 4: \geq 73 years





Plemper J, Sartorius A, Karl S. Age-Dependent Dose Increase During an Acute Electroconvulsive Therapy Series. J ECT. 2023 Sep 1;39(3):193-196.